<div>
  <p>
  </p>
  <ul>
    <li>
      <p>
        Denmark-based AI immunology company Evaxion Biotech has priced its initial public offering (IPO) of 3,750,000 American Depositary Shares (ADS) and associated warrants at USD 4.00 per ADS, raising an aggregate of USD 15 million. The offer is expected to close on February 5, 2024.
      </p>
    </li>
    <li>
      <p>
        The proceeds will be used to advance Evaxion's preclinical and clinical pipeline and support ongoing operational costs and working capital.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://investors.evaxion-biotech.com/news-releases/news-release-details/evaxion-biotech-announces-pricing-15-million-public-offering">
      Press release
    </a>
  </p>
  <p>
  </p>
</div>


AI Drug Discovery

<div>

  <p>AI immunology firm Evaxion Biotech, based in Denmark, has set the price for its initial public offering (IPO) of 3,750,000 American Depositary Shares (ADS) and related warrants at USD 4.00 per ADS. This move will collectively raise USD 15 million. The offer is set to close on February 5, 2024.</p> 
  <p>The funds raised will be put towards the advancement of Evaxion's preclinical and clinical pipeline, as well as covering ongoing operational costs and working capital.</p>

</div>

Evaxion Biotech to raise USD 15 million in IPO to fuel clinical development

All Updates

Evaxion Biotech to raise USD 15 million in IPO to fuel clinical development

Evaxio launches proprietary AI platform technology, ObsERV

Evaxion Biotech secures USD 40 million from Lincoln Park Capital

Evaxion Biotech beats analyst estimates in Q3 2021

Evaxion Biotech to raise USD 24 million in follow-on public offering

Evaxion Biotech teams up with Merck’s Keytruda